Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19330152 | 0.83 | ALDH1A1 (0.55) | KDM4EALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL26639879 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL30657473 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL6559464 | 0.76 | ALDH1A1 (0.51) | KDM4EALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL1901245 | 0.74 | ALDH1A1 (0.47) | KDM4EALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL11605385 | 0.74 | TDP1 (0.71) | KDM4EALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL1514960 | 0.72 | POLB (0.44) | KDM4EALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL143872 | 0.71 | KDM4E (0.46) | KDM4EALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL31264183 | 0.71 | KDM4E (0.46) | KDM4EALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL31582715 | 0.71 | KDM4E (0.54) | KDM4EALDH1A1POLBL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147102-B1 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-0934300-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020188132-A1 | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | WYETH HOLDINGS CORPORATION | 2002-12-12 | — | — | US | disclosed |
| US-20010051614-A1 | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | LEVIN JEREMY IAN (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1147102-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6200996-B1 | ARTHRITIS; BONE, GASTROINTESTINAL DISORDERS; CROHN*S DISEASE, MULTIPLE SCLEROSIS | AMERICAN CYANAMID COMPANY | 2001-03-13 | — | — | US | disclosed |
| US-6197795-B1 | ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS; WOUND HEALING AGENTS | AMERICAN CYANAMID COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6162814-A | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2000-12-19 | — | — | US | disclosed |
| US-6162821-A | Preparation and use of ortho-sulfonamide heteroarly hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-19 | — | — | US | disclosed |
| WO-2000044740-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-5962481-A | ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS; WOUND HEALING AGENTS;ANTIULCER AGENTS; ORAL DISEASES; CENTRAL NERVOUS SYTEM DISORDERS; ANTIINFLAMMATORY AGENTS; CONGESTIVE HEART FAILURE;VISION DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0934300-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998016520-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051614-A1 | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | MMP1, MMP12, MMP26 | KDM4E 4521/4885ALDH1A1 2216/4885POLB 742/4885 |
| US-20020188132-A1 | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | TNF, SI, MMP12 | KDM4E 4332/4885ALDH1A1 2422/4885POLB 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.